Drug profile · INN
rocuronium bromide
ROCURONIUM BROMIDE
rocuronium bromide (ROCURONIUM BROMIDE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — rocuronium bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
rocuronium bromide (ROCURONIUM BROMIDE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rocuronium bromide?
rocuronium bromide (ROCURONIUM BROMIDE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for rocuronium bromide?
ROCURONIUM BROMIDE is a marketed brand name for rocuronium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rocuronium bromide?
rocuronium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.